Latest Healthcare News

Page 3 of 182
4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.
Ada Torres
Ada Torres
27 Feb 2026
Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.
Ada Torres
Ada Torres
27 Feb 2026
SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.
Ada Torres
Ada Torres
27 Feb 2026
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.
Ada Torres
Ada Torres
26 Feb 2026
Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.
Ada Torres
Ada Torres
26 Feb 2026
Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.
Ada Torres
Ada Torres
26 Feb 2026
Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.
Ada Torres
Ada Torres
26 Feb 2026
Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.
Ada Torres
Ada Torres
26 Feb 2026
ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.
Ada Torres
Ada Torres
26 Feb 2026
Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.
Ada Torres
Ada Torres
26 Feb 2026
Sigma Healthcare has delivered a robust first half of FY26, posting a 15% rise in revenue driven by strong domestic and international sales growth, alongside operational synergies and strategic store expansions.
Ada Torres
Ada Torres
26 Feb 2026